Loading
NASDAQFinancial ServicesAsset Management - Cryptocurrency
Latest quote
$3.30
−$0.29 · -8.08%
Hyperion DeFi, Inc. is a U.S. publicly listed company that is building a long-term strategic treasury of HYPE, the native token of the Hyperliquid blockchain. The company's primary objective is to provide shareholders with streamlined access to the Hyperliquid ecosystem. Shareholders gain compounding exposure to HYPE through the token's native staking yield and additional revenues from its on-chain utility. The company also continues the development of its proprietary Optejet User Filled Device for ophthalmic applications, reflecting its transformation from its prior focus on ophthalmic technology.
Regular session
$3.30
−$0.29 · -8.08%
Regular session · ET · Market data may be delayed.
Hyperion DeFi, Inc. is a U.S. publicly listed company that is building a long-term strategic treasury of HYPE, the native token of the Hyperliquid blockchain. The company's primary objective is to provide shareholders with streamlined access to the Hyperliquid ecosystem. Shareholders gain compounding exposure to HYPE through the token's native staking yield and additional revenues from its on-chain utility. The company also continues the development of its proprietary Optejet User Filled Device for ophthalmic applications, reflecting its transformation from its prior focus on ophthalmic technology.
Day range
Current $3.30
52-week range
Current $3.30
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
51
Fair Value
Sentiment
46
Mixed
Risk
82
Extreme Risk
Momentum
20
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Hyperion DeFi, Inc. is a U.S. publicly listed company that is building a long-term strategic treasury of HYPE, the native token of the Hyperliquid blockchain. The company's primary objective is to provide shareholders with streamlined access to the Hyperliquid ecosystem. Shareholders gain compounding exposure to HYPE through the token's native staking yield and additional revenues from its on-chain utility. The company also continues the development of its proprietary Optejet User Filled Device for ophthalmic applications, reflecting its transformation from its prior focus on ophthalmic technology.
Day range
Current $3.30
52-week range
Current $3.30
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 813.46K USD | 57.34K USD | 3.79K USD | — | 14M USD |
| Cost of goods sold | 303.29K USD | 3.93M USD | 16.01K USD | — | 1.6M USD |
| Gross profit | 510.17K USD | −3.87M USD | −12.22K USD | — | 12.4M USD |
| Research and development | 1.91M USD | 14.46M USD | 12.98M USD | 13.38M USD | 14.85M USD |
| Selling, general, and administrative | 17.18M USD | 14.33M USD | 12.42M USD | 14.53M USD | 10.57M USD |
| Operating expenses | 19.49M USD | 44.87M USD | 25.39M USD | 26.91M USD | 25.42M USD |
| Interest income | 240.02K USD | 254.02K USD | 693.61K USD | 83.33K USD | 2.52K USD |
| Interest expense | 1.56M USD | 2.48M USD | 2.37M USD | 1.38M USD | 387.76K USD |
| Depreciation and amortization | — | 1.13M USD | 783.21K USD | 307.43K USD | 221.56K USD |
| Operating income | −18.98M USD | −48.74M USD | −25.41M USD | −26.91M USD | −13.02M USD |
| Net income | −45.31M USD | −49.82M USD | −27.26M USD | −28.01M USD | −12.78M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$9.82
197.58% upsideLimited analyst sample: 3 ratings. Interpret the distribution with caution.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Feb 3, 2025 | 1:80 | — | — |
Effective Feb 3, 2025
1:80
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
iShares Micro-Cap ETFIWCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
